PDCD1 and melanoma: We conducted similar analysis for two independent cohorts of melanoma patients with anti-PD-1 treatment [63], [64], but could not observe significant correlation between TI-Treg-specific expression level of TNFRSF9 with the anti-PD-1 response rate.